For citations:
Besova NS, Titova TA, Trusilova EV, Gorbunova VA, Tryakin AA, Gordeeva OO, Rumyantsev AA, Nasyrova RY, Zhukova LG, Snegovoy AV, Artamonova EV, Manzyuk LV, Fedenko AA. Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia. Meditsinskiy sovet = Medical Council. 2018;(10):34-40. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-34-40
Email this article 